Pay in 4 interest-free payments of $6.07 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
Currently, there are 3 GLP-1 agonists that are FDA-approved for the treatment of obesity: Saxenda (Liraglutide)- a once-daily subcutaneous injection given in the back of the arm, the thigh, or the abdomen
Thats why formulation strategy matters just as much as the science behind the drug
It is currently approved for the treatment of type 2 diabetes and obesity
Ashby D, Borman N, Burton J, Corbett R, Davenport A, Farrington K et al (2019) Renal Association Clinical Practice Guideline on Haemodialysis
Starting at a lower dose is commonly used to assess individual tolerance, since higher starting amounts may be associated with temporary effects such as insomnia , restlessness/anxiety , or fatigue during the adjustment phase
